Health
Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura – News-Medical.net
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP)…
In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care. The findings are being presented today at the virtual 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.
We performed the first-ever cost effectiveness analysis in acquired TTP and found that the addition of caplacizumab to standard of care treatment is not cost effective at its…
-
General19 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
General17 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News17 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW
-
Noosa News18 hours agoBack to the Future the Musical’s extraordinary visual effects mean you’ll see the DeLorean fly